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We report two cases of daptomycin (DAP)-nonsusceptible (DNS) vancomycin-intermediate Staphylococcus aureus (VISA) verte-
bral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole.
Both patients responded rapidly and favorably to this combination. The clinical isolates from the two patients were tested post
hoc in an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model to confirm the bactericidal activity and enhancement of
daptomycin and trimethoprim-sulfamethoxazole. The combination of high-dose daptomycin and trimethoprim-sulfamethoxa-
zole should be explored further for the treatment of DNS VISA strains.
Treatment of Staphylococcus aureus infections displaying de-creased susceptibility to both vancomycin and daptomycin
(DAP) is challenging. Agents that retain activity are generally bac-
teriostatic, making the clearance of bacteria in deep-seated infec-
tions like osteomyelitis difficult, or they have concerning adverse
effect profiles. This is especially true if appropriate surgical inter-
vention and debridement cannot be performed. The following
two cases illustrate the use of a novel bactericidal combination of
high-dose daptomycin and trimethoprim-sulfamethoxazole
(SXT) for the treatment of daptomycin-nonsusceptible (DNS)
vancomycin-intermediate Staphylococcus aureus (VISA) vertebral
osteomyelitis.
(A portion of this work was presented as a poster presentation
at the 51st Interscience Conference on Antimicrobial Agents and
Chemotherapy [ICAAC], Chicago, IL, 2011.)
In February 2010, an 80-year-old male with a history of meth-
icillin-resistant Staphylococcus aureus (MRSA) infections pre-
sented as an outpatient to his primary care physician with nausea,
vomiting, and hypotension. Blood cultures were obtained, and 48
h later, the Gram stain was positive for Gram-positive cocci. The
patient was admitted to the hospital and treated with vancomycin
intravenously (i.v.) after 3 days of oral linezolid therapy as an
outpatient. Results from both a three-phase nuclear bone scan and
magnetic resonance imaging (MRI) of the spine were consistent
with T9 and T10 vertebra osteomyelitis, discitis, and paravertebral
phlegmon. Surgical debridement was not considered due to the
location of the infection. A transesophageal echocardiogram was
negative for endocarditis.
On hospital day 3 (day 3 in the hospital), vancomycin was
discontinued, and 650 mg of quinupristin-dalfopristin (7.5 mg/kg
of body weight) i.v. every 8 h was initiated based on culture results.
The outpatient blood cultures had two distinct S. aureus isolates:
S. aureus H9749-1 (vancomycin MIC of 16 g/ml and daptomy-
cin MIC of 2 g/ml) and isolate two (vancomycin MIC of 2 g/ml
and daptomycin MIC of 0.5 g/ml). Both isolates were susceptible
to SXT (Table 1). On hospital day 5, the patient was switched to
daptomycin (10 mg/kg/day) plus SXT i.v. (8 mg/kg/day of the
trimethoprim [TMP] component) given every 8 h based on in
vitro evidence of bactericidal activity against a DNS heterogeneous
VISA (hVISA) strain (23). Repeat blood cultures taken on hospital
admission were negative. On hospital day 11, the patient was tran-
sitioned to oral therapy, two double-strength (DS) SXT tablets
twice daily while continuing daptomycin 10 mg/kg/day. On day 16
of hospitalization, his serum creatinine (SCr) rose to 2.0 mg/dl,
and he complained of intolerable nausea and vomiting. Daptomy-
cin (10 mg/kg/day) was continued, but the SXT dose was de-
creased to one DS SXT tablet twice daily. Twenty-four days later,
his serum creatinine returned to baseline and he was put back on
two DS SXT tablets twice daily with daptomycin (10 mg/kg/day).
The patient tolerated the daptomycin-SXT combination therapy
for 2 months when his creatinine phosphokinase (CPK) increased
to 1,280 IU/liter without symptoms of myopathy. Daptomycin
was discontinued, and the CPK level returned to baseline (17 IU/
liter). He completed 6 months of SXT suppression therapy and
was deemed a clinical cure.
In June 2010, a 65-year-old female with a history of recurrent
MRSA leg wounds with bacteremia was admitted to the hospital
with intractable back pain. A MRI of the spine showed T6 to T7
vertebral enhancement, suspicious for vertebral osteomyelitis,
with no evidence of an abscess. Surgical debridement was not
performed due to the location of the infection. On hospital day
three, the patient was switched from empirical vancomycin i.v. to
daptomycin at 6 mg/kg per day when the Gram stain method was
positive for Gram-positive cocci. Two separate peripheral blood
cultures grew S. aureus isolate F31774 with a vancomycin MIC of
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2 g/ml by automated susceptibility testing (Vitek 2), 3 g/ml
when repeated by Etest, and confirmed VISA with a MIC of 4
g/ml by the New York State reference laboratory. The daptomy-
cin MIC was 4 g/ml (Table 1). On day six, the daptomycin dose
was increased to 10 mg/kg/day, and SXT i.v. (8 mg/kg/day of the
TMP component) given every 8 h was added after repeat blood
cultures remained positive. The blood cultures were negative 48 h
later. The patient tolerated the high-dose SXT given i.v. in combi-
nation with daptomycin therapy for 7 days (hospital day 12),
while repeat blood cultures remained negative (day 10), until her
SCr increased to 2.6 mg/dl (from a baseline of 1.2 mg/dl) with
potassium of 6.0 mmol/liter, prompting the discontinuation of
SXT and replacement with oral rifampin (300 mg) given three
times daily. Her CPK increased to 164 IU/liter on day 11 of dap-
tomycin (baseline CPK 33 IU/liter) without myopathy. On day 15
of hospitalization, the patient experienced an increase in dyspnea,
and chest computed tomography (CT) revealed numerous pul-
monary nodules thought to be septic emboli from a presumed
tricuspid valve endocarditis; however, a transesophageal echocar-
diogram could not be performed. Blood cultures remained nega-
tive. Linezolid (600 mg given i.v.) every 12 h was added to provide
greater pulmonary coverage. Despite aggressive therapy, the pa-
tient died on day 19 of hospitalization.
All Staphylococcus isolates were tested using an automated
testing system, Vitek 2 (bioMérieux), vancomycin Etest strips
(bioMérieux), and sent to the New York State Health Depart-
ment for confirmation. Post hoc, isolates were then sent to the
Wayne State University Anti-Infective Research Laboratory for
confirmation of MIC by broth microdilution (BMD) via Clin-
ical and Laboratory Standards Institute (CLSI) guidelines and
synergy testing via an in vitro pharmacokinetic/pharmacody-
namic (PK/PD) model (6).
One-compartment in vitro PK/PD model. A 48-h in vitro
PK/PD one-compartment model as previously described was uti-
lized to simulate human pharmacokinetic parameters (22, 24, 25).
Pharmacodynamic samples from each model were collected over
48 h and plated for bacterial enumeration. Bactericidal activity
(99.9% kill) was defined as a >3 log10 CFU/ml reduction in colony
count from the initial inoculum. Enhancement of activity was
defined as an increase in killing of 2 log10 CFU/ml by a combi-
nation of antimicrobial agents versus the most active single agent
alone. Reductions in colony counts were determined over a 48-h
period and compared for the different regimens. Changes in
CFU/ml at 0 to 48 h were compared by one-way analysis of vari-
ance with Tukey’s Post-Hoc test. A P value of  0.05 was consid-
ered significant. All statistical analyses were performed using IBM
SPSS statistical software (release 19.0; SPSS, Inc., Chicago, IL).
MIC values measured by Vitek 2 and BMD for isolates placed
in the PK/PD models can be seen in Table 1. The activity of dap-
tomycin, vancomycin, SXT, and daptomycin plus SXT against S.
aureus strain H9749-1 in the in vitro PK/PD model are displayed in
Fig. 1A. Vancomycin and SXT were bacteriostatic, while dapto-
mycin displayed sustained bactericidal activity from 8 to 48 h. The
combination of daptomycin plus SXT was rapidly bactericidal
(8 h), reached the limit of detection (1 log10 CFU/ml) at 24 h, and
was significantly better than either agent alone (24 to 48 h) (P 
0.004).
The activity of daptomycin, vancomycin, SXT, rifampin, dap-
tomycin plus SXT, and daptomycin plus rifampin against S. au-
reus strain F31774 in the in vitro PK/PD model can be seen in Fig.
1B. Bacteriostatic activity was observed for vancomycin, dapto-
mycin, SXT, and rifampin. Daptomycin plus SXT displayed sus-
tained bactericidal activity (32 to 48 h) and was significantly better
than either agent alone at 48 h (P  0.001). Daptomycin plus
rifampin were bactericidal (24 to 48 h) and significantly better
than either agent alone (48 h) (P  0.001) and was better than
daptomycin plus SXT only at 24 h (P  0.04).
There are limited case reports of VISA bone and joint infec-
tions. Successful outcomes have been reported with linezolid
monotherapy, linezolid with fusidic acid, linezolid with rifampin,
quinupristin-dalfopristin, and a combination of vancomycin, naf-
cillin, and gentamicin (11–13, 17, 18). SXT and daptomycin have
concentration-dependent bactericidal activity against VISA/
hVISA strains and also have clinical data to support their use in the
treatment of osteomyelitis (5, 7, 9, 18, 23, 26). Multiple studies
have evaluated the safety of high-dose daptomycin and found the
incidence of symptomatic myopathy and CPK elevation to be
comparable to that of standard doses (4, 8, 10, 14, 15, 20). Dapto-
TABLE 1 Vitek 2 MICs for VISA isolates
Antimicrobial agent(s)
MICa (mg/liter) of antimicrobial agent for:
Case 1
Case 2, isolate 1
(S. aureus F31774)
Isolate 1
(S. aureus H9749-1) Isolate 2
Quinupristin-dalfopristin 0.5 1 N/A
Daptomycin 2 [2–4] 0.5 [0.25] 4 [4]
Gentamicin 0.5 0.5 0.5
Linezolid 2 4 2
Telavancin (0.38)b (1)b 0.5
SXT 0.5/9.5 [0.03/0.6] 0.5/9.5 [0.03/0.6] 0.5/9.5 [0.03/0.6]
Rifampin 32 32 0.5 [0.06]
Tigecycline 0.25 0.5 0.12
Clindamycin 8 8 8
Oxacillin 4 4 4
Vancomycin 16 [8–16] 2 2 (3)b [4]
a MIC confirmed by broth microdilution at the Anti-Infective Research Laboratory shown in brackets. N/A, not available (no quinupristin-dalfopristin disks were available due to
back order). For trimethoprim-sulfamethoxazole (SXT), the value for trimethoprim is shown before the slash and the value for sulfamethoxazole is shown after the slash.
b MIC by Etest.
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mycin regimens up to 12 mg/kg/day have been studied in healthy
patients and in patients with deep-seated VISA infections (2, 16).
In each of our patient cases, CPK levels were elevated from normal
baseline levels, but neither patient developed symptoms of myop-
athy despite these elevations. Adverse reactions of SXT include
gastrointestinal symptoms, increased serum creatinine, and hy-
perkalemia (1, 3, 19). A rise in serum creatinine in both patients
and hyperkalemia in the second patient led to reduction of the
SXT dose in the first patient and cessation of SXT therapy in the
second patient. Following cessation of SXT therapy, the second
patient experienced a rapid clinical decline. It is important to note
the in vitro data from the isolates from the two patients demon-
strate bactericidal and enhancement of activity of daptomycin and
SXT against DNS VISA at a lower dose of TMP (360 mg/day) than
what was used initially in these cases. At this lower dose, an in-
crease in creatinine is more likely due to competitive tubular se-
cretion and not a change in the actual glomerular filtration rate,
allowing patients to continue therapy and avoid switching to a
less-effective regimen (3).
Although tested post hoc, the results from our in vitro PK/PD
model correlated with the clinical outcomes. The first patient
achieved osteomyelitis resolution, and the second patient cleared
persistent bacteremia on daptomycin plus SXT. Concern has been
raised regarding the efficacy of SXT in treating infections where
high exogenous thymidine released from damaged host tissues
may be present and antagonizing SXT activity (21). The clinical
outcomes in our patients while on combination therapy with SXT
were good, despite no surgical management to remove dead tis-
sue, and correlated with the results of the in vitro model. Dapto-
mycin appeared bactericidal when combined with rifampin in our
model; however, this did not correlate with the second patient’s
clinical course and may represent an area for further research.
High-dose daptomycin combined with SXT may be a viable op-
tion for patients with DNS VISA infections.
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